Centralization and Oncologic Outcomes in Ovarian Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-99
SponsorAzienda USL Reggio Emilia - IRCCS
About this trial
This is a multicenter, observational, retrospective and prospective study conducted within the REMO (Reggio Emilia - Modena) network in the Emilia-Romagna region (Italy), promoted by AUSL-IRCCS of Reggio Emilia.
The study aims to evaluate the impact of surgical centralization and treatment strategies adopted during the COVID-19 pandemic on oncologic outcomes in patients diagnosed with the epithelial ovarian cancer (EOC) from 2018 to 2023.
The retrospective component includes patients treated between 2018 and 2023, while the prospective component consists of clinical follow-up of those patients over the next five years.
Eligibility criteria
Qualifiers
Female patients aged between 18 and 99 years
Histological and/or cytological diagnosis of epithelial ovarian cancer
Patients evaluated by the Multidisciplinary Tumor Board (MTB) of the AUSL-IRCCS of Reggio Emilia
Patients treated between January 1, 2018, and December 31, 2023
Disqualifiers
Patients without histological or cytological confirmation of epithelial ovarian cancer
Incomplete or missing data for key clinical indicators
Patients unable to provide informed consent and for whom recontact is not possible
Patients deemed unable to understand and provide consent (e.g., severe cognitive impairment)
Trial design
Treatments tested in this trial
- No Intervention: Observational Cohort
Treatment groups
200 Participants
are divided into 3 treatment groupsSponsors and collaborators
Azienda USL Reggio Emilia - IRCCS
Lead sponsor
AUSL di Modena - Ospedale Ramazzini di Carpi
Collaborator
AUSL di Modena - Ospedale di Mirandola
Collaborator
AUSL di Modena - Ospedale Civile di Sassuolo
Collaborator
AUSL di Modena - Ospedale di Pavullo nel Frignano
Collaborator
AUSL di Modena - Ospedale di Vignola
Collaborator
Azienda Ospedaliero-Universitaria di Modena
Collaborator
Source ClinicalTrials.gov